Early ALPHA3 Data Could Signal Shift to Frontline Use of CAR T in LBCL

For years, the promise of chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL) has faced stubborn limits. First, the therapy typically comes too late. Patients with blood cancers are not eligible until they relapse, and then they wait for weeks while their personalized treatment is manufactured. All the while, aggressive cancers may be advancing, requiring bridging treatments. Next, most patients must travel to specialized academic centers with staff trained to manage severe toxicities.

Data released earlier this month by Allogene Therapeutics suggest things are about to change.¹

On April 13, 2026, Allogene reported on the planned interim futility analysis of ALPHA3, a randomized phase 2 study that is evaluating cemacabtagene ansegedleucel (cema-cel) as a frontline consolidation therapy in patients with LBCL who remain minimal residual disease (MRD) positive after completing a standard first-line treatment, typically some variation of rituximab plus chemotherapy.²

In a stunning result, 58.3% of patients who received cema-cel achieved MRD negativity at day 45, compared with 16.7% in the observation arm—a 41.6–percentage point absolute difference that easily surpassed the 25% to 30% benchmark considered clinically meaningful, according to a statement from Allogene officials as well as previously published literature.^1-3

“Early MRD clearance in this setting is encouraging and supports the potential for cema-cel to change how we approach high-risk LBCL at the end of first-line therapy,” Zachary Roberts, MD, PhD, executive vice president of research and development and chief medical officer of Allogene, said in a statement. “These interim data suggest that an off-the-shelf CAR T may be able to intervene during that important window before clinical relapse to eliminate residual disease and make earlier intervention feasible in routine clinical practice. We look forward to the next study milestones as the trial continues to further define the potential of cema-cel.”¹

An Earlier Intervention, a Smarter Target

The ALPHA3 design rests on the idea that cancer may be silently progressing even when patients appear to be in remission after R-CHOP or similar treatments. Residual tumor DNA circulating in the bloodstream—which can be detected through MRD assays such as Natera's Clarity test—identifies patients whose cancer is likely to return. Rather than wait for radiographic relapse, ALPHA3 is enrolling these MRD-positive patients and randomizing them to either a single infusion of cema-cel or observation. The study is the first randomized trial in LBCL that uses this MRD-guided, proactive strategy.¹

The need for this type of intervention is seen when one examines what happens without this approach. While ctDNA levels in cema-cel–treated patients fell by a median of 97.7% from baseline at day 45, levels in the observation arm rose by a median of 26.6% over the same period—a divergence that reveals undetected disease progression in patients nominally considered stable. For the third of patients with LBCL who can be expected to relapse after first-line therapy, this window between remission and recurrence may be the best moment to act.

Why Allogeneic Matters Here

The frontline consolidation setting is precisely where having an allogeneic or “off-the-shelf” therapy matters most. Autologous CAR T-cell therapies, which are created with a patient’s own T cells, require collection, shipment to a manufacturing facility, genetic modification, quality testing, and finally infusion back into the body. The entire process can take 6 weeks or longer. For a patient in remission but at elevated risk of relapse, that timeline defeats the point of early intervention.

A donor-derived, off-the-shelf product, by contrast, can be offered within days of a treatment decision; this drastically shortens the “brain to vein” interval—the number of days between the physician’s order and the time the patient is infused.

Cema-cel is engineered to minimize the risks historically associated with allogeneic cell therapies. Researchers from Moffitt Cancer Center who spoke with The American Journal of Managed Care^® about cema-cel in 2024 described how gene editing disrupts the T-cell receptor to reduce graft-vs-host disease (GVHD) risk, and an anti-CD52 monoclonal antibody administered prior to infusion promotes engraftment and durable response.⁴ In ALPHA3, the safety profile reflected that engineering: zero cases of cytokine release syndrome, zero cases of immune effector cell–associated neurotoxicity syndrome, and zero cases of GVHD were reported among the 12 treated patients.

Of note, 10 of the 12 were managed entirely as outpatients—a sharp contrast with conventional CAR T practice, where roughly 70% to 90% of patients require hospitalization for toxicity management.⁵

Reaching Patients Beyond Academic Centers

Perhaps as consequential as the efficacy signal is where the treatment was administered. Community oncology clinics—including sites with little to no prior CAR T-cell therapy experience—accounted for approximately one-third of both screening activity and cema-cel infusions in the interim analysis, according to Allogene officials.¹ This aligns with the current strategy seen in administration of bispecific therapies, where for cost and convenience reasons, the move is on to treat patients in outpatient and community settings wherever possible, reducing travel time and other barriers to access.

“In busy community practices, the goal is simple: bring the therapy to the patient, not the patient to the therapy,” said Jeff Sharman, MD, chair, Lymphoma Research Executive Committees, SCRI at Willamette Valley Cancer Institute & Research Center, in a statement. “Historically, CAR T has largely been out of reach for community practices. The ability to deliver an off-the-shelf CAR T safely in the community setting, potentially outpatient, could address far more patients and extend treatment reach across the communities we serve.”¹

Primary Results in 2027

The interim futility analysis, drawn from the first 24 randomized patients, was designed to determine whether the trial should continue—not to establish definitive efficacy. The primary end point of event-free survival (EFS), along with secondary end points of progression-free survival and overall survival, remains blinded. Full enrollment of approximately 220 patients is anticipated by the end of 2027, with an interim EFS analysis expected in mid-2027 and the primary EFS readout in mid-2028. A positive result would support a biologics license application filing, according to the statement from Allogene.¹

References

1. Allogene Therapeutics reports interim futility analysis from pivotal ALPHA3 trial showing 58.3% MRD clearance with cemacabtagene ansegedleucel (cema-cel) vs. 16.7% in observation arm in first-line consolidation LBCL. News release. Allogene. April 13, 2026. Accessed April 23, 2026. https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-interim-futility-analysis-pivotal
2. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
3. Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. 2025;393:2395-2408. doi:10.1056/NEJMoa2511885
4. Caffrey M. T-cell exhaustion in CLL: allogeneic CAR T trial reaching patients with unmet need. Am J Manag Care. 2024;30(Spec. No. 5):SP417.
5. Majhail NS, Cox T, Larson S, et al. Outpatient administration of chimeric antigen receptor T-cell therapy using remote patient monitoring. JCO Oncol Pract. 2025;21(11):1601-1608. doi:10.1200/OP-25-00062